IL-PRICEFX
16.12.2020 15:32:08 CET | Business Wire | Press release
Pricefx , the global leader in cloud-native pricing software, today launched Velo, a unique offering for companies to maximize value on large deal negotiations. Designed to manage the largest transactional relationships in each business, Velo is the industry’s first solution specifically focused on helping sellers to prepare for, and win, profit-maximizing outcomes on large contract negotiations, bids, proposals and sourcing events. Combining a proven deal negotiation methodology with innovative technology for value estimation and leverage optimization, Velo now gives businesses the analytical insights, structured process and workflow automation to negotiate highly customized deals with confidence.
For many large B2B companies, the top 5-10% of their customers make up more than 50% of revenue. The agreements with those customers are essential to the company’s survival. With changes in demand, both buyers and sellers seek to optimize their largest positions as contracts and commitments naturally expire or get adjusted. Buyers often use powerful procurement platforms to optimize their position. With Velo, companies can now equip themselves with an equally powerful package of technology and strategy to maximize value, optimize leverage and negotiate to win.
“Companies have traditionally relied on spreadsheets and manual processes, without collaborative tools, thus leaving potential negotiation power unknown,” said Marcin Cichon, CEO and co-founder at Pricefx. “We are giving businesses a powerful, new way to manage large, complex deals, leveling the playing field in negotiations, and improving outcomes. Tribal wisdom and outdated CPQ technology are no match for the capabilities of Velo.”
“Procurement organizations continue to attack the profit and value positions of their largest suppliers,” said Brian Sharp, Chief Revenue Officer for Profit Velocity. “Category-by-category, sellers face a withering storm of sourcing event approaches with software and services geared toward depleting supplier profits and value. Velo is the first solution to re-balance the playing field so that suppliers can capture their fair share of the value they create for their largest customers.”
Pairing Pricefx ValueEstimator and LargeDealOptimizer modules with the proven methodology from partner Profit Velocity, Velo is a one-of-a-kind strategic software solution to maximize profitability and leverage in large deals. It pairs this software with a proven process-centered methodology, leveraging leading-edge scenario-based negotiation playbooks and a team of negotiation experts who have managed over 400 large complex deals with cumulative recurring revenues exceeding $8 Billion/year across a multitude of industry verticals.
LargeDealOptimizer facilitates the planning of large, complex deals with guidance and contextual information to support the negotiation of monolithic deals in one, central location. It manages deal teams through the workflow of establishing opening positions, anticipating buyer objections and counter-proposals, while aligning the team with their leadership’s objectives and governance. Efficiently streamlining, organizing, and approving complex customer transactions within the Pricefx platform, LargeDealOptimizer enables organizations to get the most value and profit from the customers that generate much of their revenue.
ValueEstimator enables companies to assess their differential competitive value based on the actual customer-based decision drivers. It establishes value-based pricing while enabling that value to be communicated when a price is set for a customer quote or proposal.
Velo provides a proven, immersive and agile service led by world-class negotiation experts, assuring business leaders and P&L owners that each deal team is ready to negotiate-to-win. While every large deal is customized by their very nature, the Velo solution provides a repeatable process-centered approach which fully integrates the new software tools. Early customer reviews of Velo say that Pricefx is offering “a unique new capability that connects its powerful price optimization engine to customer value data. We've waited a long time for this – a huge breakthrough for pricing leaders.”
Velo is easy-to-deploy and can be delivered one deal at-a-time or through a subscription-based approach to support the highest stakes deals. Historically businesses have consistently grown the profitability of their large customer transactions by an average of 440 basis points per deal by leveraging the Velo software and methodology.
Availability
Velo is available now and interested parties can learn more at www.hellovelo.com
.
About Profit Velocity Solutions LLC
A San Francisco-based data analytics software company, Profit Velocity has pioneered the use of time-based profit data analytics that enable the management teams of large manufacturers to fine-tune their mix of customers and products and unlock significant investor gains. With its unique profit data visualizations and instant what-if planning, Profit Velocity’s profit information platform turns readily available data into potent new insights that allow decision-makers to isolate and capture gains previously buried in an ocean of corporate data. Profit Velocity has served manufacturers, large and small, across North America, Asia, and Europe. For more information, please visit www.profitvelocity.com
.
About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201216005113/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
